Oncology Central

Further insight into AE37 peptide vaccination in prostate cancer

0

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host [1]. Although the rationale of cancer vaccination studies seems to be promising, therapeutic efficacy is rather limited [2,3]. One reason that could account for that is the inappropriate clinical trial design and patient selection, rather than the vaccine itself [3].

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.